Santa Monica, CA – John Wayne Cancer Institute and the Los Angeles Clinic and Research Institute

Melanoma Clinical Trials- Recruiting

Phase
NCT01013623
Stage IV Surgery Versus Best Medical Therapy		 Phase III
NCT01048554
Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System		 Phase II
NCT00788775
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma		 Phase II
NCT01335009
Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma		 Phase II
NCT01127451
Study of ONTAK in Patients With Stage IIIC and Stage IV Melanoma		 Phase II
NCT01152788
A Randomized Phase II Study of Interleukin-21 (rIL-21) Versus Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma		 Phase II
NCT01029873
Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma		 Phase I, Phase II
NCT01397708
Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma		 Phase I
NCT01011530
Dose Escalation Study of MLN4924 in Adults With Melanoma		 Phase I
NCT00815607
Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma		 Phase I
Updated from clinicaltrials.gov on 8/24/2011

Comments are closed.